Clinical trial
Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)
NCT00368082 · Baylor College of Medicine, Other · Active, not recruiting
Key facts
| NCT number | NCT00368082 |
|---|---|
| Title | Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) |
| Official title | Administration of TGF-b Resistant LMP-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma |
| Acronym | TGF-beta |
| Lead sponsor | Baylor College of Medicine, Other |
| Collaborators | The Methodist Hospital Research Institute Center for Cell and Gene Therapy, Baylor College of Medicine |
| Status | Active, not recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Hodgkin's Disease, Relapse, Non-Hodgkin |
| Intervention type | Biological |
| Interventions | TGFbeta resistant LMP-specific CTLs |
| Enrollment | 8 |
| Start date | Apr 1, 2006 |
| Primary completion | Sep 1, 2013 |
| Completion | Jul 1, 2031 |
| First posted | Aug 24, 2006 |
| Last update posted | Oct 31, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: